MDXG: MiMedx Group Company Value to Net Income

Symbol and logo of brand MiMedx Group Inc (MDXG)

MiMedx Group, Inc. (MDXG) specializes in the development of regenerative biologics, with profits driven by insurance reimbursements and hospital procurement. The price-to-earnings ratio provided by GURU.Markets, this chart of which captured a value of -24.00, confirms market expectations. Updated transparent management and dominance in the placental products niche, backed by a robust research base, create a significant barrier to entry for competitors.

P/E Multiple: MiMedx Group (MDXG) for 07/04/2022 - 11/13/2026

Comprehensive metric breakdowns and analytics for MiMedx Group (MDXG)

- price and consensus price forecast:
Stock Price mimedx.com|MDXG - Consensus Target
- market capitalization information:
Market Value MiMedx Group, Inc.|MDXG - Total Company Value
- balance sheet net asset value indicators:
Accounting Value per Share MiMedx|MDXG - Book Capitalization|Market-to-Book Ratio mimedx.com|MDXG - Cumulative Company Assets
- company liabilities and liquidity data:
Aggregate Debt to Capital MiMedx Group, Inc.|MDXG - Long-Term Debt to Capital|Short-Term Debt to Capital MiMedx Corp|MDXG - Company Aggregate Debts|Debt to Book Capitalization Ratio MiMedx Group, Inc.|MDXG - Company Long-Term Debt|Short-Term Debt MiMedx|Quick Liquidity mimedx.com
- company profitability and valuation multiples indicators:
MDXG - Net Profit|Company Profit Forecast MiMedx Group, Inc.|MDXG - Price to Earnings Ratio|Market Cap to Projected Earnings MiMedx Group Inc|MDXG - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio MiMedx Group, Inc.|MDXG - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months MiMedx|MDXG - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months mimedx.com|MDXG - Earnings per share growth in current year|Expected earnings per share growth for next year MiMedx Group, Inc.
Summary company analysis:mimedx.com
Finished products of MiMedx Group

The P/E ratio determines the cost of a single unit of net profit, reflecting investors' market expectations regarding business growth rates. By analyzing the P/E valuation metric, one can assess the degree of asset overheating, which is critically important for MiMedx Group, Inc. (MDXG) due to its dependence on a narrow segment of placental products and stringent regulatory oversight within the regenerative medicine sector.

Analysis of competing companies

P/E Multiple ascendispharma.com|Price to Earnings Ratio MDGL (Madrigal Pharmaceuticals, Inc.)|CORT (Corcept Therapeutics Inc.) - Company Value to Net Income|Price to Earnings Ratio Rhythm Pharmaceuticals Inc RYTM|AKRO - Price to Earnings Ratio|Metsera Inc - P/E Multiple|Market Cap to Earnings moonlaketx.com|CRNX (Crinetics) - Price to Earnings Ratio|NAMS: Market Price to Net Income Ratio|SLNO (Soleno) - P/E Multiple|P/E Multiple Amicus Corp|P/E Multiple ETNB|Price to Earnings Ratio AGIO (agios.com)|Price to Earnings Ratio Structure Therapeutics Inc. GPCR|Rezolute Inc (RZLT) - Market Cap to Earnings|LXRX - Price to Earnings Ratio|MBX: Price to Earnings Ratio|ALT: P/E Multiple|AARD - Business Payback Period|Price to Earnings Ratio Sagimet Biosciences Inc.|BioAge Labs (BIOA) - Business Payback Period|Price to Earnings Ratio Biomea (BMEA)|Price to Earnings Ratio quincetx.com QNCX|Price to Earnings Ratio Fractyl Health, Inc. GUTS|VTVT - Price to Earnings Ratio|Agape ATP Corp. - P/E Multiple|Business Payback Period Pluri Inc. PLUR|synlogictx.com (SYBX) - Price to Earnings Ratio|Price to Earnings Ratio Lipocine Corporation|MTNB (Matinas BioPharma Holdings, Inc.) - P/E Multiple|Market Cap to Earnings sprucebiosciences.com SPRB|P/E Multiple GLTO|Carmell Corp. - Price to Earnings Multiple|Lumos Pharma Corp - Price to Earnings Ratio|ONVO: Price to Earnings Multiple|RDUS: Price to Earnings Ratio